Clene Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs
Clene (NASDAQ: CLNN) releases Q2 2024 financial results and updates on CNM-Au8(R) programs. Optimism about potential submission of new drug application for ALS and Rett Syndrome treatment.
This news matters because it provides insight into the progress of a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. The updates on CNM-Au8(R) programs for ALS and Rett Syndrome offer hope for patients and their families, with the potential for a new drug application submission later this year.